SYMPOSIUM. BENIGN PROSTATIC HYPERPLASIA (BPH). WHAT LIES AHEAD? Epidemiology and evaluation. Guidelines for the diagnosis of lower urinary tract symptoms in men. BPH and PSA: Correlation and management. Nocturia: advances in diagnosis and treatment. BPH: Guidelines for Medical Management and alternative therapies. • Effect of 5α-Reductase inhibitors in the BPH. Erectile dysfunction (ED) associated syndrome. Tadalafil alone or combined to manage BPH: The new frontier? Phytotherapy and BPH Surgical Treatment: New minimal invasive technologies. HoLEP vs Greenlight Laser. Laser therapy: enucleation vs vaporization.
Evaluation and management of Uro- Genital pain. Interstitial Cystitis and Bladder pain Syndrome: is a problem for men too. Urodynamics: dynamic study, evolving and subject to interpretation. Evaluation and management of neurogenic bladder in adults. Contemporary Pharmacotherapy of the Overactive Bladder. Is Sacral Neuromodulation the best alternative? BotulinumToxin:whentouseit, for whatdoyouuseitandwhicharethe outcomes. Pollen extract with vitamins vs Serenoa Repens in chronic prostatitis and chronic pelvic pain syndrome.
SYMPOSIUM. PROSTATITIS, CHRONIC PELVIC PAIN, HYPERACTIVE BLADDER.
Urinary tract infections: Emerging Processes and Clinical Guidelines. Chronic nonbacterial prostatitis: where are we? Chronic prostatitis in the patient with prostate cancer. The role of uncommon bacteria in chronic prostatitis and chronic pelvic pain syndrome.
SYMPOSIUM. I PROSTATE CANCER: EPIDEMIOLOGY, NATURAL HISTORY, DETECTION, STAGING AND PROGNOSIS.
Vaccines against Prostate Cancer, current state of research. Selective Androgen Receptor Modulators (SARMS): current status report.
Made with FlippingBook flipbook maker